Cargando…

A study on the anti-osteoporosis mechanism of isopsoralen based on network pharmacology and molecular experiments

OBJECTIVE: Osteoporosis (OP) is a disease caused by multiple factors. Studies have pointed out that isopsoralen (IPRN) is one of the most effective drugs for the treatment of OP. Based on network pharmacological and molecular experimental analysis, the molecular mechanism of IPRN in osteoporosis is...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jian, Chen, Tianyu, Li, Xiang, Zhang, Yu, Fu, Shuang, Huo, Ruikun, Duan, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108469/
https://www.ncbi.nlm.nih.gov/pubmed/37069639
http://dx.doi.org/10.1186/s13018-023-03689-6
_version_ 1785026854691799040
author Wang, Jian
Chen, Tianyu
Li, Xiang
Zhang, Yu
Fu, Shuang
Huo, Ruikun
Duan, Yan
author_facet Wang, Jian
Chen, Tianyu
Li, Xiang
Zhang, Yu
Fu, Shuang
Huo, Ruikun
Duan, Yan
author_sort Wang, Jian
collection PubMed
description OBJECTIVE: Osteoporosis (OP) is a disease caused by multiple factors. Studies have pointed out that isopsoralen (IPRN) is one of the most effective drugs for the treatment of OP. Based on network pharmacological and molecular experimental analysis, the molecular mechanism of IPRN in osteoporosis is clarified. METHODS: IPRN target genes and OP-related genes were predicted from the databases. Intersections were obtained and visualized. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed on target genes, which was confirmed by experiments internal and external experiments. Molecular docking was used to verify the binding between IPRN and target proteins. Molecular dynamics (MD) simulates the binding affinity of protein targets and active compounds. RESULTS: 87 IPRN target genes and 242 disease-related targets were predicted. The protein–protein interaction (PPI) network identified 18 IPRN target proteins for the treatment of OP. GO analysis indicated that target genes were involved in biological processes. KEGG analysis showed that pathways such as PI3K/AKT/mTOR were associated with OP. Cell experiments (qPCR and WB) found that the expressions of PI3K, AKT, and mTOR in MC3T3-E1 cells at 10 μM, 20 μM, and 50 μM IPRN concentrations, especially at 20 μM IPRN treatment, were higher than those in the control group at 48 h. Animal experiments also showed that compared with the control group, 40 mg/kg/time IPRN could promote the expression of the PI3K gene in chondrocytes of SD rats. CONCLUSIONS: This study predicted the target genes of IPRN in the treatment of OP and preliminarily verified that IPRN plays an anti-OP role through the PI3K/AKT/mTOR pathway, which provides a new drug for the treatment of OP.
format Online
Article
Text
id pubmed-10108469
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101084692023-04-18 A study on the anti-osteoporosis mechanism of isopsoralen based on network pharmacology and molecular experiments Wang, Jian Chen, Tianyu Li, Xiang Zhang, Yu Fu, Shuang Huo, Ruikun Duan, Yan J Orthop Surg Res Research Article OBJECTIVE: Osteoporosis (OP) is a disease caused by multiple factors. Studies have pointed out that isopsoralen (IPRN) is one of the most effective drugs for the treatment of OP. Based on network pharmacological and molecular experimental analysis, the molecular mechanism of IPRN in osteoporosis is clarified. METHODS: IPRN target genes and OP-related genes were predicted from the databases. Intersections were obtained and visualized. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed on target genes, which was confirmed by experiments internal and external experiments. Molecular docking was used to verify the binding between IPRN and target proteins. Molecular dynamics (MD) simulates the binding affinity of protein targets and active compounds. RESULTS: 87 IPRN target genes and 242 disease-related targets were predicted. The protein–protein interaction (PPI) network identified 18 IPRN target proteins for the treatment of OP. GO analysis indicated that target genes were involved in biological processes. KEGG analysis showed that pathways such as PI3K/AKT/mTOR were associated with OP. Cell experiments (qPCR and WB) found that the expressions of PI3K, AKT, and mTOR in MC3T3-E1 cells at 10 μM, 20 μM, and 50 μM IPRN concentrations, especially at 20 μM IPRN treatment, were higher than those in the control group at 48 h. Animal experiments also showed that compared with the control group, 40 mg/kg/time IPRN could promote the expression of the PI3K gene in chondrocytes of SD rats. CONCLUSIONS: This study predicted the target genes of IPRN in the treatment of OP and preliminarily verified that IPRN plays an anti-OP role through the PI3K/AKT/mTOR pathway, which provides a new drug for the treatment of OP. BioMed Central 2023-04-17 /pmc/articles/PMC10108469/ /pubmed/37069639 http://dx.doi.org/10.1186/s13018-023-03689-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wang, Jian
Chen, Tianyu
Li, Xiang
Zhang, Yu
Fu, Shuang
Huo, Ruikun
Duan, Yan
A study on the anti-osteoporosis mechanism of isopsoralen based on network pharmacology and molecular experiments
title A study on the anti-osteoporosis mechanism of isopsoralen based on network pharmacology and molecular experiments
title_full A study on the anti-osteoporosis mechanism of isopsoralen based on network pharmacology and molecular experiments
title_fullStr A study on the anti-osteoporosis mechanism of isopsoralen based on network pharmacology and molecular experiments
title_full_unstemmed A study on the anti-osteoporosis mechanism of isopsoralen based on network pharmacology and molecular experiments
title_short A study on the anti-osteoporosis mechanism of isopsoralen based on network pharmacology and molecular experiments
title_sort study on the anti-osteoporosis mechanism of isopsoralen based on network pharmacology and molecular experiments
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108469/
https://www.ncbi.nlm.nih.gov/pubmed/37069639
http://dx.doi.org/10.1186/s13018-023-03689-6
work_keys_str_mv AT wangjian astudyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT chentianyu astudyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT lixiang astudyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT zhangyu astudyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT fushuang astudyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT huoruikun astudyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT duanyan astudyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT wangjian studyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT chentianyu studyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT lixiang studyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT zhangyu studyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT fushuang studyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT huoruikun studyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments
AT duanyan studyontheantiosteoporosismechanismofisopsoralenbasedonnetworkpharmacologyandmolecularexperiments